Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that is focused on discovering and developing innovative therapies to treat liver disease and cancer. The company's pipeline includes several drug candidates that are being developed to treat non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and hepatocellular carcinoma (HCC). Terns Pharmaceuticals was founded in 2016 and is headquartered in Brisbane, California.